|
|
| Welcome to LeukemiaLinks,
your monthly source of leukemia news, research
updates, clinical trials and events sponsored
by The Leukemia & Lymphoma Society
(LLS). For even more information, regularly
visit our Patient
Services and Disease
Information Web
sections. | |
 |
|
|
|
LLS Features
::READ MORE::
.....................................................................................................................................
Research
Roundup ::READ MORE::
.....................................................................................................................................
IRC Question of
the Month
:: READ
MORE::
| |
|
Inspirational
Stories
 Learn
how individuals touched by blood cancer
cope. The LLS LifeMosaic
Web feature offers hundreds of
inspiring stories by patients and families. Read
them or submit
your
own. |
Here to
Help
For even more information,
regularly visit the LLS Web site, www.LLS.org, where many of our education programs
are archived free of charge for convenient
access 24/7.
If you haven't found what
you're looking for in LeukemiaLinks ,
please call our Information Resource Center
(IRC) to speak with trained information
specialists. IRC staff are available Monday
through Friday, 9 a.m. to 6 p.m. ET, toll free
at (800) 955-4572; email infocenter@lls.org; or click the "Live Patient Help" button
on the www.LLS.org homepage.
| |
|
|
Commentary
Certain cancer drugs can
cause heart problems. Learn what scientists
are doing to help patients. :: READ
MORE::
Clinical
Trials
We
invite you to use our Clinical
Trial Service, a free and confidential
service that can help you find clinical trials
that meet your needs.
You may also
want to visit the National Cancer Institute's Cancer
Trials Support Unit, providing resources and
information on Phase III cancer treatment trials
supported by the National Cancer
Institute. :: SELECTED
TRIALS::
Newsfeeds &
Podcasts
Now
you can get RSS Feeds and Podcasts from LLS.
:: CLICK HERE TO SIGN
UP::
Free
eNewsletters
Free LLS
eNewsletters deliver the latest information on
research and treatment options, patient services
programs and fundraising events.
::CLICK HERE TO SIGN UP
::
| | | |
| 
| | | |
|
|
|
Treanda
Approved for CLL Patients
The U.S.
Food and Drug Administration approved
bendamustine hydrochloride
(Treanda®), an intravenously
administered alkylating agent, for the treatment
of patients with chronic lymphocytic leukemia
(CLL).
Drug
Not Linked with Secondary Cancers in Children
with ALL
Dexrazoxane, used to
prevent anthracycline-induced myocardial
toxicity, does not appear to increase the risk
of secondary malignant neoplasms in children
with high-risk acute lymphoblastic leukemia
(ALL), according to the Journal of
Clinical
Oncology.
>
Back to the
top | |
|
My
Personal CML Journey
LLS is proud to
offer My Personal CML
Journey, an interactive, online video
education program. The feature follows the
stories and experiences of two chronic
myelogenous leukemia (CML) survivors. Learn
more.
CML
Therapy: Making History, Making
Progress
This recent
program featured Brian J. Druker,
M.D., of Oregon Health & Science
University. Check back soon for an archived
version and transcript.
Archived
Programs on Sexuality and Young Adults with
Cancer
LLS has several programs on
these important survivorship issues.
They feature Sage Bolte, M.S.W., L.C.S.W.,
of Life with Cancer®, Inova Cancer
Services. They can be accessed for free
24/7.
New
Podcasts
Too busy to
participate in a live LLS telephone education
program? Listen to an archived version by
adding our podcast feeds to your computer.
Podcast audio files are sent to
you automatically and feature leading
medical experts discussing a wide range of blood
cancer-related topics. There are many podcasts
to choose from, including seven new feeds
dedicated to recent teleconferences. Sign up
today. It's easy.
LLS
Blog
Check out
the new LLS blog for patients and
caregivers. The blog features top blood
cancer-related news and provide
personal stories from the folks
who are most affected by blood
cancers - patients and the ones who care for
them. The blog is completely interactive; you
can respond to people's posts. And while you're
there, visit our Cancer Centers
section.
Take
Action
As survival
rates increase for the estimated 20,000 children
under the age of 21 diagnosed with cancer in the
United States each year, so do complications
resulting from their treatment. U.S. Reps. Hilda
L. Solis and Mary Bono Mack have introduced
legislation to enhance the study and treatment
of these "late effects" of treatment for
childhood cancer survivors. Please, urge your
member of Congress to co-sponsor H.R. 4450
today.
Co-Pay Assistance
Program
Qualified
patients who have difficulty paying for
their health insurance premiums or prescription
drug co-pays can now apply for assistance from
LLS.
The Leukemia &
Lymphoma Society is committed to curing blood
cancers and helping patients and their families.
Learn
the many ways you can help advance the Society's
mission.
Find out
more about our other
eNewsletters.
> Back to the
top
| |
|
Phase I-II study of
oxaliplatin, fludarabine, cytarabine and
rituximab combination therapy in patients with
Richter's syndrome or fludarabine-refractory
chronic lymphocytic leukemia ::READ MORE::
Cardiomyopathy in
children with Down syndrome treated for acute
myeloid leukemia: a report from the Children's
Oncology Group Study POG 9421
::READ MORE::
Sorafenib induces
apoptosis of AML cells via Bim-mediated
activation of the intrinsic apoptotic
pathway ::READ MORE::
Post-traumatic stress
disorder and risk factors in parents of children
with a cancer diagnosis
::READ MORE::
Safety and efficacy of
ofatumumab, a fully human monoclonal anti-CD20
antibody, in patients with relapsed or
refractory B-cell chronic lymphocytic leukemia:
a Phase I-II study ::READ
MORE::
Lenalidomide for the
treatment of B-cell malignancies ::READ MORE::
> Back to the
top
| |
 We invite you to use
our Clinical
Trial Service , a free and confidential
service that can help you find clinical trials
that meet your needs. You may also want to visit
the National Cancer Institute's Cancer
Trials Support Unit, providing resources and
information on phase III cancer treatment trials
supported by the National Cancer Institute.
Selected Trials
Genetic Study of Patients with
Acute Myeloid Leukemia, Acute Lymphoblastic
Leukemia, Myelodysplastic Syndromes or Multiple
Myeloma ::READ MORE::
Phase III: Vaccine Therapy and
GM-CSF in Treating Patients with Acute Myeloid
Leukemia in Remission ::READ MORE::
Phase III: Imatinib versus
Nilotinib in Adult Patients with a Suboptimal
Cytogenetic Response with Philadelphia
Chromosome Positive (Ph+) Chronic Myelogenous
Leukemia in Chronic Phase (CML-CP) (ENEST)
::READ MORE::
Phase III: Early or Delayed
Fludarabine and Rituximab in Treating Patients
with Previously Untreated Chronic Lymphocytic
Leukemia ::READ MORE::
> Back to the
top
| |
IRC Question of
the Month: Integrative
Medicine
| 
Q: I've
heard about using integrative medicine as part
of cancer treatment. Can you tell me what this
is?
A: Integrative medicine
supports the use of some complementary and
alternative medicine (CAM) therapies - those
that have been found to be safe and effective -
in addition to conventional cancer therapies,
such as drug therapy, radiation therapy and
immunotherapy.
CAM therapies include support groups,
therapeutic massage, acupuncture, meditation,
yoga, art therapy and music therapy, among
others. There is no scientific evidence to date
that any CAM therapies will slow cancer
progression. However, some cancer patients say
that an integrative medicine approach helps
them to cope with their disease and
treatment, to feel better and to have a sense of
control over their health.
Studies are ongoing to evaluate CAM therapies
and to determine those that are safe and
effective for people living with leukemia,
lymphoma, myeloma, myelodysplastic
syndromes and other diseases. It is
important for patients to talk openly with their
treatment teams about any CAM therapies they are
currently using or considering using.
LLS has a fact sheet about integrative
medicine with information about CAM therapies,
including questions to ask your physician and
how to locate licensed IM and CAM providers. Click here to read a copy
online.
As always, we encourage patients, their
families and caregivers to turn to the IRC for
information and support. IRC specialists are
available 9 a.m. to 6 p.m. ET. Call us with your
questions at (800)
955-4572.
> Back to the
top
| |
| | | |
|
|
 |
Supported by an
unrestricted
educational grant
from
 |
 |
|
Contact Us: The
Leukemia & Lymphoma Society, 1311 Mamaroneck
Ave., White Plains, NY 10605, (800)
955-4572
|
|
| Visit our e-Store
& Special Offers page where you can
support businesses that support
LLS. | | | | | |
|
| | | |
